Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Vir Biotechnology, Inc. VIR

Healthcare  —  Biotechnology
10.66 (0.06) (0.56%) as of 25 Sep
Market cap
$1.8B
P/E
0.0×
Dividend Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Vir Biotechnology, Inc. (VIR) Business Profile

Updated before January 2025

Company Overview

Vir Biotechnology, Inc. (VIR) is a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology aims to address some of the world’s most challenging infectious diseases, including influenza, hepatitis B, HIV, and COVID-19. The company was co-founded by Robert Nelsen and has since grown under the leadership of its CEO, Marianne De Backer, Ph.D., who joined the company in 2023. Vir’s leadership team comprises seasoned professionals with extensive experience in biotechnology, pharmaceuticals, and immunology, driving the company’s mission to transform the treatment of infectious diseases.

Core Business Segments

Vir Biotechnology operates across several core business segments, focusing on the development of innovative therapies for infectious diseases. These segments include:

Antibody Therapeutics

Vir is renowned for its work in monoclonal antibodies, which are engineered to target specific pathogens. One of its most notable products is Sotrovimab, a monoclonal antibody developed in collaboration with GlaxoSmithKline (GSK) for the treatment of COVID-19. Sotrovimab has received Emergency Use Authorization (EUA) in multiple countries and has been a critical tool in combating the pandemic.

Vaccines

Vir is actively involved in vaccine development, leveraging its expertise in immunology to create vaccines for diseases such as influenza and hepatitis B. The company collaborates with leading organizations to accelerate vaccine development and distribution.

Antiviral Therapies

Vir is developing small-molecule antiviral drugs to target a range of infectious diseases. These therapies aim to inhibit the replication of viruses, providing a robust treatment option for patients.

Immune Modulation

The company is also exploring immune modulation therapies, which aim to enhance the body’s natural immune response to fight infections. This segment includes research into T-cell therapies and other innovative approaches.

Business Model

Vir Biotechnology’s business model is built on a combination of proprietary research, strategic partnerships, and revenue generation through product sales and licensing agreements. The company invests heavily in research and development (R&D) to create groundbreaking therapies. It also collaborates with pharmaceutical giants like GSK to co-develop and commercialize products, sharing both the risks and rewards. Revenue is primarily generated through product sales, milestone payments, and royalties from licensing agreements. This diversified approach allows Vir to sustain its operations while pursuing long-term growth opportunities.

Strategic Direction

Vir Biotechnology has a clear strategic vision focused on expanding its product portfolio, enhancing global access to its therapies, and achieving sustainability goals. Key elements of its strategic direction include:

  • Pipeline Expansion: Vir is actively working to expand its pipeline of therapies, with a focus on diseases with high unmet medical needs, such as HIV and hepatitis B.
  • Global Access: The company is committed to ensuring that its therapies are accessible to patients worldwide, particularly in low- and middle-income countries.
  • Sustainability: Vir aims to minimize its environmental footprint by adopting sustainable practices in its operations and supply chain.
  • Innovation: The company continues to invest in cutting-edge technologies, such as CRISPR and AI, to accelerate drug discovery and development.

Competitive Landscape

Vir Biotechnology operates in a highly competitive environment, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its monoclonal antibody therapies, including those for COVID-19.
  • Moderna: A leader in mRNA vaccine technology, competing in the infectious disease space.
  • Pfizer: A global pharmaceutical giant with a strong presence in vaccines and antiviral therapies.
  • Gilead Sciences: Focused on antiviral therapies, particularly for HIV and hepatitis.
  • BioNTech: A pioneer in mRNA-based therapies and vaccines.

Despite the competition, Vir differentiates itself through its focus on immunology and its strategic partnerships.

Risk Factors

Like any biotech company, Vir Biotechnology faces several risks, including:

  • Market Dependence: The company relies heavily on the success of a few key products, such as Sotrovimab. Any decline in demand or regulatory challenges could impact revenue.
  • Supply Chain Disruptions: Global supply chain issues could affect the production and distribution of its therapies.
  • Regulatory Risks: The biotech industry is heavily regulated, and delays or failures in obtaining regulatory approvals could hinder product launches.
  • Competition: Intense competition from other biotech and pharmaceutical companies could limit market share.
  • R&D Uncertainty: The success of Vir’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.

Recent Developments

Vir Biotechnology has made significant strides in recent years, including:

  • COVID-19 Response: The company played a pivotal role in the fight against COVID-19 with the development of Sotrovimab. It continues to monitor emerging variants and adapt its therapies accordingly.
  • Partnerships: Vir has strengthened its collaboration with GSK and other partners to accelerate the development of new therapies.
  • Pipeline Progress: The company has advanced several candidates in its pipeline, including therapies for hepatitis B and influenza.
  • Global Expansion: Vir has expanded its global footprint, establishing partnerships and operations in key markets worldwide.

Investment Considerations

Investors considering Vir Biotechnology should weigh the following factors:

Strengths

  • Innovative Pipeline: Vir has a robust pipeline of therapies targeting high-impact diseases.
  • Strategic Partnerships: Collaborations with industry leaders like GSK enhance its capabilities and market reach.
  • Strong Leadership: The company is led by experienced professionals with a proven track record in biotech.

Risks

  • Market Dependence: Reliance on a few key products poses a risk to revenue stability.
  • Regulatory Challenges: Delays or failures in obtaining approvals could impact growth.
  • Competition: Intense competition in the biotech space could limit market opportunities.

Conclusion

Vir Biotechnology, Inc. is a dynamic player in the biotech industry, leveraging its expertise in immunology to address some of the world’s most pressing health challenges. With a strong pipeline, strategic partnerships, and a commitment to innovation, Vir is well-positioned for future growth. However, investors should carefully consider the risks associated with the biotech sector before making investment decisions.